Worldwide, hemophilia patients are getting access to lifesaving drugs that help blood clotting, thanks to a new effort by activists and drug makers.
Hemophilia patients around the world are getting new access to lifesaving drugs that help their blood to clot properly, thanks to an unusual effort by activists and pharmaceutical companies to not only give away the medication, but ensure it reaches families in need.
Biogen, based in Cambridge, Mass., has teamed up with the World Federation of Hemophilia to create a supply chain that is meant to ensure millions of donated units of the drug traverse the globe in cold storage, make it through customs, and arrive in clinics in Africa, Asia, and Central America without being diverted to the black market.
Biogen and its Stockholm-based partner, Sobi, are donating enough medicine over the next five years to treat tens of thousands of bleeding episodes and give prophylactic treatment to children under 5, which is the standard of care in the US but has rarely been done in developing countries.
Read Full Article: Hemophilia patients in developing world gain access to vital drug
|Read Full Article: Hemophilia patients in developing world gain access to vital drug|